Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 3/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | ALPG | P10696 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953721 | 0.84 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1MEN1KMT2AEPHX1 | |
| SCHEMBL22582183 | 0.83 | DYRK1A (0.39) | L3MBTL1MEN1KMT2AEPHX1POLB | |
| SCHEMBL22236157 | 0.83 | EPHX1 (0.53) | L3MBTL1ALDH1A1MEN1KMT2AEPHX1 | |
| SCHEMBL8219219 | 0.79 | CCR8 (0.57) | L3MBTL1ALDH1A1MEN1KMT2APARP1 | |
| SCHEMBL959324 | 0.79 | CNR1 (0.49) | L3MBTL1ALDH1A1MEN1KMT2APARP1 | |
| SCHEMBL1286716 | 0.78 | CNR1 (0.54) | L3MBTL1ALDH1A1MEN1KMT2APARP1 | |
| SCHEMBL1286743 | 0.78 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1MEN1KMT2AEPHX1 | |
| SCHEMBL8261368 | 0.78 | HDAC4 (0.51) | L3MBTL1ALDH1A1MEN1KMT2APARP1 | |
| SCHEMBL2031057 | 0.78 | ALDH1A1 (0.49) | ALDH1A1EPHX1CNR1 | |
| SCHEMBL12426680 | 0.77 | HDAC4 (0.61) | L3MBTL1ALDH1A1MEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008058-B | Prodrugs of CDK inhibitors for the treatment of cancer | 润佳（苏州）医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-111848579-B | Prodrugs of 4- (2, 6-dichlorobenzoylamino) -N- (4-piperidinyl) -1H-pyrazole-3-carboxamide | 君实润佳(上海)医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20230000881-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| CN-114008058-A | Prodrugs of CDK inhibitors for the treatment of cancer | 润佳（苏州）医药科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3786164-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | Ting Therapeutics LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3310783-B1 | COMPOSITIONS FOR THE PREVENTION OF HEARING LOSS | TING THERAPEUTICS LLC (US) | 2020-11-04 | — | — | EP | disclosed |
| CN-111848579-A | Prodrugs of 4- (2, 6-dichlorobenzamido) -N- (4-piperidinyl) -1H-pyrazole-3-carboxamide | 润佳（苏州）医药科技有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200179397-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2020-06-11 | — | — | US | disclosed |
| US-20060194843-A1 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections; 4-(2,6-difluoro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methyl-piperidin-4-yl)-amide | ASTEX THERAPEUTICS LIMITED (GB) | 2006-08-31 | — | — | US | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| EP-1651612-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | Astex Therapeutics Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000881-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | CDK2, CDK5, CDK20 | L3MBTL1 1184/4885ALDH1A1 3101/4885MEN1 875/4885 |
| US-20200179397-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | CDK2, CDK5, CDK20 | L3MBTL1 1184/4885ALDH1A1 3101/4885MEN1 875/4885 |
| US-20060194843-A1 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections; 4-(2,6-difluoro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methyl-piperidin-4-yl)-amide | CDK1, CDK3, ROS1 | L3MBTL1 2272/4885ALDH1A1 3745/4885MEN1 1468/4885 |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | CDK3, CDK1, GSK3B | L3MBTL1 2802/4885ALDH1A1 1686/4885MEN1 1537/4885 |
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | CDK3, CDK1, GSK3B | L3MBTL1 2802/4885ALDH1A1 1686/4885MEN1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.